[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601306":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":38,"locations":47,"responsibleParty":63,"collaborators":42,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":68,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":42,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":42,"overallStatus":50,"whyStopped":42,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"L-carnitine group","ACTIVE_COMPARATOR","This group will receive the standard chemotherapy protocol (cisplatin -based chemotherapy) plus L-carnitine 350 mg (L-carnitine®) three times daily by oral.",[13],"Drug: L-Carnitine Tartrate",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo group","PLACEBO_COMPARATOR","This group will receive the standard chemotherapy protocol (cisplatin -based chemotherapy) plus placebo tablets with the same criteria of the intervention drug and the same dose.",[19],"Drug: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","L-Carnitine Tartrate","L-carnitine 350 mg three times daily by oral.",[9],[27],"L-Carnitine, Levocarnitine, carnitine",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo","placebo tablet three times daily by oral.",[15],[33],"Matching placebo, inactive control",[35],{"name":36,"affiliation":5,"role":37},"Fatma M Eweda, Master","PRINCIPAL_INVESTIGATOR",[39,44],{"name":36,"role":40,"phone":41,"phoneExt":42,"email":43},"CONTACT","+201017045245",null,"fatma.mamdouh7376@phrm.menofia.edu.eg",{"name":45,"role":40,"phone":42,"phoneExt":42,"email":46},"Fatma M Eweda","fatmamamdouh203@gmail.com",[48],{"facility":49,"status":50,"city":51,"state":42,"zip":42,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Menoufia Clinical Oncology Department, Menoufia University.","RECRUITING","Shibīn al Kawm","Egypt","EG",{"type":55,"coordinates":56},"Point",[57,58],31.00904,30.55258,{"lat":58,"lon":57},[61],{"name":62,"role":40,"phone":42,"phoneExt":42,"email":42},"Menoufia Clinical Oncology Department, Menoufia University, M",{"type":37,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"Fatma Mamdouh Elsayed Eweda","Teaching Assistant","100601306","phase-2-l-carnitine-protective-effect-in-nephrotoxicity-100601306",false,"NCT07108777","L-Carnitine Protective Effect in Nephrotoxicity","Clinical Study to Evaluate the Possible Protective Effect of L-Carnitine Against Cisplatin-Induced Nephrotoxicity","LC","Inclusion Criteria:\n\n* Male or female patients.\n* Newly diagnosed patients with cancer and with an indication for cisplatin - based chemotherapy.\n* Age between 18 and 75 years.\n* No serious cardiopulmonary comorbidity which could impair involvement in the study.\n* Creatinine clearance value above 50 mL\u002Fmin\u002F1.73 m².\n* Patients who will scheduled to receive at least 3 cycles of cisplatin.\n* Patients with no previous renal diseases (including acute nephropathy, acute and chronic renal failure).\n\nExclusion Criteria:\n\n* Pregnancy or lactation.\n* Metastasis to the central nervous system.\n* Psychiatric disorders.\n* Prior treatment with platinum derivatives.\n* Hypersensitivity to cisplatin, carboplatin or other platinum derivatives.\n* Patients with active infection or any symptoms of sepsis.\n* Acute renal failure or renal surgery within the last 3 months.\n* Patients unfit for cisplatin (patients with impaired renal function, sensorineural hearing loss and cardiomyopathy).\n* Patients with known history or current treatment with nephrotoxic agents.\n* Taking other antioxidant supplements such as Vitamins C and E.","ALL","18 Years","75 Years",{"count":78,"type":79},46,"ESTIMATED","INTERVENTIONAL",[82],"PHASE2","The goal of this clinical trial is to assess the possible reno-protective effect of L-carnitine against cisplatin-induced nephrotoxicity in patients receiving cisplatin-based chemotherapy. The main question it aims to answer is:\n\nDoes L-carnitine have the ability to protect the kidney against cisplatin-induced nephrotoxicity?",[85],"Nephrotoxicity","2025-08-09",{"date":88,"type":89},"2025-08-12","ACTUAL",{"date":91,"type":89},"2025-08-10",{"date":93,"type":79},"2026-11-01",{"name":5,"class":6},1]